Preview

PULMONOLOGIYA

Advanced search

Outcomes of community-acquired pneumonia

https://doi.org/10.18093/0869-0189-2015-25-1-101-105

Abstract

Russian and international data on community-acquired pneumonia (CAP) morbidity were analyzed. At Sverdlovsk region, mortality of CAP was reduced in all age groups after CAP monitoring system had been implemented but morbidity of CAP is still growing. Analysis of published data showed that cardiovascular system is often affected in patients with pneumococcal CAP due to direct pneumococcus invasion to the myocardium. One of the main measures for CAP control is still immune prevention with conjugate pneumococcus vaccines which is primary intended for high-risk groups.

About the Author

E. S. Korovkina
Federal institution “I.I.Mechnikov Scientific and Research Vaccine and Serum Institute”, Russian Science Academy: 5A, Malyy Kazennyy per., Moscow, 105064, Russia
Russian Federation

PhD, Senior Researcher of Laboratory of Vaccine Prevention and Immune Therapy of Allergic Diseases, Federal institution “I.I.Mechnikov Scientific and Research Vaccine and Serum Institute”, Russian Science Academy; tel. / fax: 495) 917-49-00;



References

1. ​Lozano R., Naghavi M., Foreman K. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380 (9859): 2095–2128.

2. ​WHO Media Center 2014. The top 10 causes of death. Available at http://www.who.int/mediacentre/factsheets/fs310/en/

3. ​WHO 2009. Acute Respiratory Infections (Update September 2009). Available at: http://www.who.int/vaccine_research/diseases/ari/en/index3.html

4. ​Чучалин А.Г., Синопальников А.И., Козлов Р.С. и др. Внебольничные пневмонии у взрослых: практические рекомендации по диагностике, лечению и профилактике: пособие для врачей. М.: РРО, МАКМАХ; 2010: 106.

5. ​Чучалин А.Г., Синопальников А.И., Козлов Р.С. и др. Клинические рекомендации по диагностике, лечению и профилактике тяжелой внебольничной пневмонии у взрослых. М.: РРО, МАКМАХ; 2014.

6. ​Романенко В.В., Сомова А.В. Эпидемиологические особенности внебольничной пневмонии в Свердловской области. Эпидемиология и вакцинопрофилактика. 2014; 2 (75): 59–65.

7. ​Лещенко И.В., Бобылева З.Д., Трифанова Н.М. и др. Клинико-организационный алгоритм ведения больных внебольничной пневмонией: методические рекомендации. Под ред. А.Г.Чучалина. Екатеринбург; 2012.

8. ​Bewick T., Sheppard C., Greenwood S. et al. Serotype prevalence in adults hospitalised with pneumococcal non-invasive community-acquired pneumonia. Thorax. 2012; 67 (6): 540–545.

9. ​WHO Weekly Epidemiological Record. 2007; 82: 93–104. Available at: http://www.who.int/wer/2007/wer8212.pdf

10. ​Musher D.M., Rueda A.M., Kaka A.S., Mapara S.M. The association between pneumococcal pneumonia and acute cardiac events. Clin. Infect. Dis. 2007; 45 (2): 158–165.

11. ​Corrales-Medina V.F., Musher D.M., Wells G.A. et al. Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality. Circulation. 2012; 125 (6): 773–781.

12. ​Brown A.O., Mann B., Gao G. et al. Streptococcus pneumoniae translocates into the myocardium and forms unique microlesions that disrupt cardiac function. PLoS Pathog. 2014; 10 (9): e1004383.

13. ​Harrison LH. Prospects for vaccine prevention of meningococcal infection. Clin. Microbiol. Rev. 2006; 19 (1): 142–164.

14. ​WHO Publication. Pneumococcal vaccines WHO position paper (2012) recommendations. Vaccine. 2012; 30 (32): 4717–4718. DOI: 10.1016/j.vaccine.2012.04.093

15. ​Чучалин А.Г. Современные подходы к вакцинопрофилактике пневмококковой инфекции у взрослых и пациентов групп риска: резолюция Междисциплинарного совета экспертов. Пульмонология. 2012, 6: 139–142.

16. ​Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb. Mortal. Wkly Rep. 2012; 61 (40): 816–819.

17. ​Tomczyk S., Bennett N.M., Stoecker C. et al. Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged #> 65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb. Mortal. Wkly Rep. 2014; 63 (37): 822–825.

18. ​Игнатова Г.Л., Родионова О.В. Клиническая эффективность вакцинации конъюгированной пневмококковой вакциной пациентов с хронической бронхолегочной патологией в Городском пульмонологическом центре Челябинска. Пульмонология, 2014, 6: 38–42.


Review

For citations:


Korovkina E.S. Outcomes of community-acquired pneumonia. PULMONOLOGIYA. 2015;25(1):101-105. (In Russ.) https://doi.org/10.18093/0869-0189-2015-25-1-101-105

Views: 4146


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)